Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography
- Conditions
- Prostate Cancer
- Interventions
- Device: Fluourine-18 Fluoromethylcholine PET/CT Imaging
- Registration Number
- NCT01310192
- Lead Sponsor
- Queen's Medical Center
- Brief Summary
The purpose of this project is to develop and evaluate fluorine-18 (F-18) fluorocholine (FCH) positron emission tomography (PET) as an imaging technique that can be used to delineate malignant tumors in the prostate gland. The proposed technique works by measuring the tissue metabolism of FCH, a substrate that is preferentially metabolized by cancer cells due to malignant over-expression of the choline transporter and choline kinase enzyme. The project scope covers a clinical study to recruit men with prostate cancer who have elected treatment by radical prostatectomy surgery. These men will undergo pre-operative PET scanning to measure F-18 FCH uptake in anatomical sextants of the prostate gland. Imaging results will be compared to histopathologic analyses of the prostatectomy specimen to determine the accuracy of F-18 FCH PET for detecting cancerous prostate sextants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 20
- Clinically Organ Confined Prostate Cancer Electing Radical Prostatectomy
- Weight > 300 lb
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Fluourine-18 Fluoromethylcholine PET/CT Imaging Investigational Imaging Device
- Primary Outcome Measures
Name Time Method Histopathologic Diagnosis - sextant diagnosis by whole-prostate step section histopathologic analysis Immediate - no longitudinal data collected
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tripler Army Medical Center
🇺🇸Tripler AMC, Hawaii, United States